SynB1-ELP-p50i

SynB1-ELP-p50i is a novel polypeptide biologic consisting of a cell-penetrating peptide (SynB1) fused to an elastin-like polypeptide (ELP) drug carrier and a specific peptide inhibitor of the nuclear factor kappa B (NF-κB) p50 subunit (p50i). Developed by the University of Mississippi Medical Center and Leflore Technologies, it acts as a competitive inhibitor of NF-κB nuclear translocation by mimicking the NF-κB nuclear localization signal. This prevents the transport of NF-κB to the nucleus, thereby reducing neuroinflammation and the production of pro-inflammatory cytokines such as TNF-α and IL-6. SynB1-ELP-p50i is being investigated in preclinical models for the treatment of ischemic stroke, traumatic brain injury (TBI), preeclampsia, and chronic kidney disease (CKD) with left ventricular diastolic dysfunction (LVDD).

Other names

ELP-p50iELP-p-50iELP-p 50iSynB1-ELP-p50i peptideSynB-1-ELP-p50i peptideSynB 1-ELP-p50i peptide